The online version of this article (https://doi.org/10.1007/s12325-019-01105-2) contains supplementary material, which is available to authorized users.
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.9885899.
Influenza is an important cause of morbidity and mortality in Europe. Prevention by annual vaccination is most effective but with yearly vaccine reformulation to match circulating virus strains, vaccine safety must be continuously monitored. The European Medicines Agency published guidance on safety monitoring of influenza vaccines.
An enhanced safety surveillance study of GSK’s inactivated quadrivalent influenza vaccine (IIV4) was conducted in Belgium, Germany, and Spain in influenza season 2018/19. The objective was to collect adverse event (AE) reports from subjects within 7 days of vaccination. A customized AE reporting card (AERC) with predefined AEs of interest was used to rapidly detect and evaluate potential new safety concerns. Interim results are presented here.
Between week 40 and 52, 1060 vaccinated subjects were enrolled (31.0% Belgium, 26.2% Germany, and 42.7% Spain) covering all ages for which IIV4 is indicated (32.0% aged 6 months–17 years, 33.8% 18–65 years, and 34.2% over 65 years). Pediatric subjects less than 9 years old (n = 139) received two doses. Following dose 1 and dose 2, 98.2% and 100%, respectively, returned the completed AERC recording any AEs. Following dose 1 and dose 2, 454 and 34 subjects, respectively, reported at least one AE (most frequently expected general and injection site symptoms and respiratory symptoms).
All reported AEs were expected as per summary product characteristics (smPC). No safety signals that impact public health or alter the benefit–risk profile of GSK’s IIV4 were identified. Subjects from all vaccinated age groups were enrolled and the use of AERCs allowed rapid monitoring and analysis of reported AEs.
ClinicalTrials.gov identifier, NCT03688620.
GlaxoSmithKline Biologicals SA.
Supplementary material 1 (DOCX 102 kb)12325_2019_1105_MOESM1_ESM.docx
Cassini A, Colzani E, Pini A, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018;23(16).
World Health Organisation (WHO). Fact Sheets. Influenza (seasonal). http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed 1 Apr 2019.
World Health Organization (WHO). Influenza vaccines. http://www.who.int/influenza/vaccines/en/. Accessed 1 Apr 2019.
European Medicines Agency (EMA). Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165492.pdf. Accessed 1 Apr 2019.
European Medicines Agency (EMA). Explanatory note on the withdrawal of the Note for guidance on harmonisation of requirements for influenza vaccines and of the core SmPC/PL for inactivated seasonal influenza vaccines. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/explanatory-note-withdrawal-note-guidance-harmonisation-requirements-influenza-vaccines-core-summary_en-0.pdf. Accessed 1 Apr 2019.
De Lusignan S, Correa A, Dos Santos G, et al. Brand specific, near real time, enhanced safety surveillance of influenza vaccines in general practice winter 2015/16: feasibility study. JMIR Public Health Surveill. 2019;10:12016.
de Lusignan S, Ferreira F, Damaso S, et al. Enhanced passive surveillance of influenza vaccination in England, 2016–2017: an observational study using an adverse events reporting card. Human Vaccines Immunother. 2019;15(5):1048–59. CrossRef
de Lusignan S, Dos Santos G, Byford R, et al. Enhanced safety surveillance of seasonal quadrivalent influenza vaccines in english primary care: interim analysis. Adv Ther. 2018;35(8):1199–214. CrossRef
Medicines.org.uk. Package leaflet. Fluarix Tetra suspension for injection in pre-filled syringe 2018. https://www.medicines.org.uk/emc/files/pil.3021.pdf. Accessed 1 Apr 2019.
Dos Santos G, Yeakey A, Shende V, et al. Passive enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season. BMJ Open. 2019;9(8):e028043. CrossRef
Medical Dictionary for Regulatory Activities MedDRA. https://www.meddra.org/basics. Accessed 1 Apr 2019.
European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccines 2019. https://ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/seasonal-influenza-vaccines.. Accessed 12 Sept 2019.
Korn EL, Graubard BI. Confidence intervals for proportions with small expected number of positive counts estimated from survey data. Survey Methodol. 1998;24(2):193–201.
Medicines.org.uk. Fluarix Tetra Summary of Product Characteristics (SmPC). 2018. https://www.medicines.org.uk/emc/product/3021/smpc. Accessed 18 May 2019.
Spila Alegiani S, Alfonsi V, Appelgren EC, et al. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season. BMC Public Health. 2018;18(1):1401. CrossRef
van Balveren-Slingerland L, Kant A, Harmark L. Web-based intensive monitoring of adverse events following influenza vaccination in general practice. Vaccine. 2015;33(19):2283–8. CrossRef
Dos Santos G. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives. Human Vaccines Immunother. 2019;22:1–13.
- Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis
Gael Dos Santos
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II